Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $32 to $22.
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $32 to $22.